Cargando…
Live-imaging rate-of-kill compound profiling for Chagas disease drug discovery with a new automated high-content assay
Chagas disease, caused by the protozoan intracellular parasite Trypanosoma cruzi, is a highly neglected tropical disease, causing significant morbidity and mortality in central and south America. Current treatments are inadequate, and recent clinical trials of drugs inhibiting CYP51 have failed, exp...
Autores principales: | Svensen, Nina, Wyllie, Susan, Gray, David W., De Rycker, Manu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8530327/ https://www.ncbi.nlm.nih.gov/pubmed/34634052 http://dx.doi.org/10.1371/journal.pntd.0009870 |
Ejemplares similares
-
Development of Trypanosoma cruzi in vitro assays to identify compounds suitable for progression in Chagas’ disease drug discovery
por: MacLean, Lorna M., et al.
Publicado: (2018) -
Rate-of-Kill (RoK) assays to triage large compound sets for Chagas disease drug discovery: Application to GSK Chagas Box
por: Cantizani, Juan, et al.
Publicado: (2021) -
Comment on “The translational challenge in Chagas disease drug development” by Kratz et al.
por: De Rycker, Manu
Publicado: (2022) -
Anti-trypanosomatid drug discovery: progress and challenges
por: De Rycker, Manu, et al.
Publicado: (2022) -
A Static-Cidal Assay for Trypanosoma brucei to Aid Hit Prioritisation for Progression into Drug Discovery Programmes
por: De Rycker, Manu, et al.
Publicado: (2012)